Zacks Investment Research
18 Dec 2025, 13:46 UTC · 43w ago
Verdict
Headline takes no side. We score CHE +0.40 across four claims — moderately bullish.
+0.40moderately bullish
More positive than 68% of ticker scores this week
Scored by the NIS engine · methodology.
What the story claims
4 claims · scored −1 bearish … +1 bullish
Chemed's VITAS segment is on track to fully mitigate potential impact from the Florida Medicare cap billing limitation in fiscal 2026, aided by a new program in Pasco County and an upcoming expansion into Marion County.
So whatResolution of a major regulatory overhang (Medicare cap) removes a significant earnings risk for the company's primary growth driver, supporting a re-rating of the stock.
More positive than 94% of claims this week
Chemed stock has underperformed significantly, dropping 17.4% over the past year compared to the industry's 6.2% rise and the S&P 500's 17.9% growth.
Continue reading
5 related stories
Top 1 mover · tap to explore
More negative than 84% of claims this week
VITAS Q3 2025 growth was driven by a 2.5% increase in days-of-care and an approximately 4.1% geographically weighted average Medicare reimbursement rate increase.
So whatSolid volume and pricing growth in the core hospice segment demonstrates fundamental resilience and pricing power against macro headwinds.
More positive than 75% of claims this week
Roto-Rooter achieved modest revenue growth of 1.1% year over year in Q3 2025 with branch performance higher than anticipated despite ongoing consumer sentiment and spending pressures.
More positive than 56% of claims this week
Which stocks this story touches
More positive than 68% of ticker scores this week
Strong operational growth in VITAS and resilience in Roto-Rooter, though offset by macroeconomic headwinds and recent stock underperformance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
6h ago
+18.6%
Price agrees with the score
$511.37 vs $431.24 close before publication (Dec 17) · not market-adjusted
CHE chart →
